Safety of topical calcineurin inhibitors in atopic dermatitis: Evaluation of the evidence
- 1 July 2006
- journal article
- review article
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 6 (4) , 270-274
Abstract
Topical calcineurin inhibitors (pimecrolimus, Elidel, East Hanover, NJ; and tacrolimus, Protopic, Tokyo, Japan) have been approved for the use in atopic dermatitis since the year 2000. These compounds represent a relatively safe class of topical anti-inflammatory, nonsteroidal therapy. However, in January of 2006, the US Food and Drug Administration issued a black box warning on these compounds about possible concerns of increased long-term malignancy risk due to systemic immunosuppression. To date, studies from clinical trials, systemic absorption, and post-marketing surveillance show no evidence for this systemic immunosuppression or increased risk for any malignancy.Keywords
This publication has 28 references indexed in Scilit:
- Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005Journal of Allergy and Clinical Immunology, 2006
- Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents’ quality of life: A multicenter, randomized trialPediatric Allergy and Immunology, 2005
- Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointmentJournal of the American Academy of Dermatology, 2005
- A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitisBritish Journal of Dermatology, 2005
- Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studiesJournal of the American Academy of Dermatology, 2005
- Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationJournal of the American Academy of Dermatology, 2005
- Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patientsArchives of Disease in Childhood, 2003
- Topical PimecrolimusDrugs, 2002
- Nonmelanoma skin cancer in the United States: IncidenceJournal of the American Academy of Dermatology, 1994